SPY424.94-0.32 -0.08%
DIA343.79-0.51 -0.15%
IXIC14,078.70-95.45 -0.67%

Insider Trends: Insider Buying Added to with Purchase of Karyopharm Therapeutics Stock

05/11/2021 05:14

09:00 AM EDT, 05/11/2021 (MT Newswires) -- On May 07, 2021, Dr Jatin Shah, EVP, Chief Medical Officer, bought 23,250 shares in Karyopharm Therapeutics (KPTI) for $199,992. Subsequent to the Form 4 filing with the SEC, Dr Shah owns 131,802 shares of the company, which have a market value of $1.08 million as of the prior-day closing price.

In the 90 days previous to the date of this filing, there have been 21 insider transactions reported to the SEC for Karyopharm Therapeutics. These transactions came from the activities of 9 different insiders that resulted in a net acquisition of 768,442 company shares. In the preceding 90-day window of time, there were 12 transactions from 8 insiders and resulted in the net acquisition of 82,300 shares.

This level of insider transactions is below that of the peer group average in the 324-company Bio Therapeutic Drugs peer group over the last 90-day period. Peer group activity averaged 60.1 transactions per company, with company insiders acquiring on average 36,336 shares.

SEC Story Link http://www.sec.gov/Archives/edgar/data/1503802/000120919121031481/xslF345X03/doc4.xml

This report does not constitute a recommendation to purchase or sell any security and the analysts are not registered investment advisors. Further analysis is recommended before undertaking any position in any security. Any risks are solely the responsibility of the buyer/seller. The authors, publishers and distributors of the MT Newswires Live Briefs service and any associates thereof accept no liability for the content or actions taken by anyone or institution utilizing this report.